Let's break down Steris (STE) — from its financial performance to how the market is valuing the stock.
Top-Line Growth
Steris reported revenue of $5.94B in FY2026, a 8.7% increase from $5.46B in FY2025.
The 10-year revenue CAGR of 10.2% is a good number — Steris's top line has expanded meaningfully from $2.24B to $5.94B.
Steris's $5.94B revenue base puts it in the mid-cap bracket among US health care companies.
Steris has posted revenue growth for 10 consecutive years — that's a sustained trend, not a one-off.
| Year | Revenue | YoY % |
|---|---|---|
| FY2026 | $5.94B | +8.7% |
| FY2025 | $5.46B | +6.2% |
| FY2024 | $5.14B | +13.3% |
| FY2023 | $4.54B | +7.4% |
| FY2022 | $4.22B | +35.9% |
Explore the full 10-year revenue trend with interactive charts
Business Segments
Looking under the hood at Steris's revenue mix for FY2025.
| Segment | Revenue | % of Total |
|---|---|---|
| Product | $2.87B | 52.6% |
| Service | $2.59B | 47.4% |
Product makes up 52.6% of revenue, clearly the primary business for Steris.
Looking at geographic exposure, Steris's revenue comes from United States (73%), Other foreign locations (25%), and Ireland (2%).
Profitability Analysis
A 27.7% improvement in net income took Steris's bottom line to $785.1M in FY2026.
The company squeezed out better margins in FY2026, with net margin at 13.2% versus 11.3% in FY2025.
On a per-share basis, diluted earnings were $7.93 in FY2026 versus $6.20 in FY2025.
See Steris's full margin history and earnings breakdown
How Steris Returns Cash to Shareholders
In FY2026, Steris distributed $2.45 per share in dividends (1.13% yield).
With 10+ consecutive years of dividend payments, Steris has a proven track record of returning cash to shareholders.
A 30.9% payout ratio is well-managed — Steris returns a healthy share of earnings while keeping enough for growth.
| Year | DPS | Payout Ratio |
|---|---|---|
| FY2026 | $2.45 | 30.9% |
| FY2025 | $2.22 | 35.8% |
| FY2024 | $2.02 | 53.0% |
| FY2023 | $1.83 | 171.1% |
| FY2022 | $1.66 | 66.9% |
On the buyback front, Steris has spent $1.15B repurchasing shares over 11 years, reducing the float and boosting per-share metrics.
View the full share repurchase and dilution trend
Financial Health
| Metric | Value |
|---|---|
| Cash & Short-term Investments | $439.6M |
| Total Debt | $1.93B |
| Shareholders' Equity | $7.20B |
| Total Assets | $10.74B |
| Debt-to-Equity Ratio | 0.27x |
| Current Ratio | 2.09x |
| Interest Coverage | 18.2x |
| Free Cash Flow (TTM) | $972.4M |
Balance sheet strength is evident: $439.6M in cash and equivalents, $1.93B in total debt, and a manageable 0.27x D/E ratio.
At 2.09x, Steris's current ratio suggests solid short-term financial flexibility.
With interest coverage at 18.2x, Steris's operating income comfortably exceeds its interest obligations.
Steris generated $972.4M in free cash flow, providing ample capacity for dividends, buybacks, and debt reduction.
Explore Steris's full balance sheet and cash flow analysis below
Steris reported a headcount of 18,000 in FY2025, about $303.3K in revenue per employee.
See Steris's full employee count history and revenue per employee
What Is Steris Worth?
Let's put a fair value on Steris using three independent valuation approaches.
Steris shares are currently trading at $210.19.
The P/E Ratio model estimates an intrinsic value of $388, implying a 45.8% upside from the current price.
We also calculate intrinsic value using the DCF and EPS Growth models. Sign up to see the full breakdown with fair value estimates.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | $388 | 45.8% upside to fair value |
| DCF | Upgrade | Upgrade |
| EPS Growth | Upgrade | Upgrade |
Investment Snapshot
What should investors take away from Steris's (STE) latest numbers? Here's the summary.
Revenue of $5.94B in FY2026, up 8.7% year-over-year.
Long-term revenue has been compounding at 10.2% annually over 10 years.
The company is profitable, with a net margin of 13.2% and net income of $785.1M.
Returned $477.3M to shareholders in FY2026 through dividends and/or buybacks.
Conservative balance sheet with a D/E ratio of 0.27x.
The P/E Ratio model implies 45.8% upside to fair value. The remaining 2 models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
The detailed charts and valuation models below provide a deeper look at Steris's financial trajectory.